NEW YORK – Fulgent Genetics reported after the close of the market on Tuesday that its fourth quarter revenues grew 48 percent year over year.
For the three months ended Dec. 31, 2019 the company reported revenues of $8.4 million, up from $5.7 million in Q4 2018. The firm said that it delivered 13,977 billable tests during Q4, more than double the number of tests in the prior-year period.